Clinical Trials Directory

Trials / Completed

CompletedNCT02456480

Pharmacodynamics of Omiganan (CLS001) in Patients With Atopic Dermatitis

A Randomized, Double-blind, Placebo Controlled Study to Assess the Pharmacodynamics, Safety/Tolerability and Efficacy of Omiganan in Patients With Mild to Moderate Atopic Dermatitis

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
37 (actual)
Sponsor
Maruho Co., Ltd. · Industry
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

To assess the pharmacodynamics, safety/tolerability, and efficacy of omiganan in patients with mild to moderate atopic dermatitis (AD).

Conditions

Interventions

TypeNameDescription
DRUGCLS001topical gel
DRUGVehicletopical gel

Timeline

Start date
2015-05-01
Primary completion
2015-11-01
Completion
2015-11-01
First posted
2015-05-28
Last updated
2016-07-28

Locations

1 site across 1 country: Netherlands

Source: ClinicalTrials.gov record NCT02456480. Inclusion in this directory is not an endorsement.

Pharmacodynamics of Omiganan (CLS001) in Patients With Atopic Dermatitis (NCT02456480) · Clinical Trials Directory